肿瘤细胞免疫治疗行业发展概况

Industry progress in cancer cell-immunotherapy

肿瘤细胞免疫治疗一般被分为非特异性和特异性细胞免疫治疗,后者中的肿瘤特异性嵌合抗体T细胞(Chimeric Antigen Receptor T cell,CAR-T)疗法已成为国内外生物制药公司竞相追逐的热点.随着人类对自身免疫系统和肿瘤发生机制研究的不断深入,细胞免疫治疗已逐渐成为现代肿瘤治疗方法中的第4种治疗手段,成为当前国际肿瘤医学发展的重要方向之一,有望成为最终治愈肿瘤的方法.作者主要综述肿瘤细胞免疫治疗的研究进展、关键技术,行业的发展状况及存在的问题,并对其进行展望.

Cell- immunotherapy in cancer treatment are usually divided into non- specific immunotherapy and specific immunotherapy. The CAR- T( Chimeric Antigen Receptor T cell) therapy treatment has become global biopharmaceutical company pursued hotspot in specific immunotherapy. With further study of the human immune system mechanisms and tumorigenesis,cell- immunotherapy treatment is called the fourth cancer treatment now,it has become one of the important directions of the current international medical oncology development,and expected to become the ultimate cure for cancer methods. In this thesis,the development and existing problems for cell immunotherapy treatment of tumors and key technology are introduced,and are prospected.